Stock Price Quote

LASA SUPERGENERICS LTD.

NSE : LASABSE : 540702ISIN CODE : INE670X01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE21.970.13 (+0.6 %)
PREV CLOSE ( ) 21.84
OPEN PRICE ( ) 22.28
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 49793
TODAY'S LOW / HIGH ( )21.61 22.93
52 WK LOW / HIGH ( )17.25 40.95
NSE22.000.2 (+0.92 %)
PREV CLOSE( ) 21.80
OPEN PRICE ( ) 22.25
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 262157
TODAY'S LOW / HIGH( ) 21.50 22.85
52 WK LOW / HIGH ( )17.1 41.2
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 11-03 2016
Management Info
Omkar Pravin Herlekar - Chairman Omkar Pravin Herlekar - Managing Director
Registered Office

Address C-4, C-4/1, M I D C,Lote Parshuram Industrial Area,Tal- Khed,
Ratnagiri Dist,
Maharashtra-415722

Phone 02145 232101/232202

Email info@lasalabs.com

Website www.lasalabs.com

Registrars Details
Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE, NSE

NEWS

07Jun Lasa Supergenerics informs about postp
Pursuant to Regulations 29 and Regulation 30 of the Securities and Excha..
28Nov Lasa Supergenerics informs about discl
Pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure..
26Aug Lasa Supergenerics informs about outco
Pursuant to Regulation 30 of SEBI (Listing Obligation and Discourse Requ..
27Apr Lasa Supergenerics secures new order o
Lasa Supergenerics has secured a new order of Rs 50 crore from just 5 cu..
27Apr Lasa Supergenerics zooms on securing n
Lasa Supergenerics is currently trading at Rs. 60.00, up by 2.10 points..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-14.58-386.21
Gross Profit -20.64 -422.66
Operating Profit 10.57-47.8900000000001
Net Sales 266.61295.68

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26946.00 (0.74%)
M.Cap ( in Cr)57258.37
Sanofi India (BSE)
peergroup  8118.25 (2.06%)
M.Cap ( in Cr)18696.83
Dr. Reddy's Lab (BSE)
peergroup  6155.15 (1.78%)
M.Cap ( in Cr)102679.14
Divi's Lab (BSE)
peergroup  3436.75 (2.14%)
M.Cap ( in Cr)91234.91
Glaxosmithkline Phar (BSE)
peergroup  1943.10 (3.26%)
M.Cap ( in Cr)32917.29

Shareholding Pattern

PROMOTERS 53.65%
NON-INSTITUTION 46.34%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Lasa Supergenerics Ltd.

Lasa Supergenerics Ltd. was incorporated in the year 2016. Its today's share price is 21.97. Its current market capitalisation stands at Rs 110.07 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1295.68 Cr and Total Income of Rs.1314.11 Cr. The company's management includes Manali Bhagtani, Ekta Avtar Gurnasinghani, Ajay Sukhwani, Hardesh Raja Tolani, Mitti Jain, Shivanand Gajanan Hegde, Omkar Pravin Herlekar, Omkar Pravin Herlekar.

It is listed on the BSE with a BSE Code of 540702 , NSE with an NSE Symbol of LASA and ISIN of INE670X01014. It's Registered office is at C-4, C-4/1, M I D C,Lote Parshuram Industrial Area,Tal- KhedRatnagiri Dist-415722, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Shah & Kathariya, Thanawala & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.